Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 1.00 |
| ▸ | KCNJ1 | P48048 | 14/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227791 | 0.85 | MAOA (0.74) | MAOAKCNJ1KCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL8661674 | 0.84 | MAOA (0.72) | MAOAKCNJ1KCNH2HRH3 | |
| SCHEMBL11029533 | 0.83 | KCNJ1 (0.81) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL2731306 | 0.82 | KCNJ1 (1.00) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL5653299 | 0.80 | HRH3 (0.93) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL3156895 | 0.80 | HRH3 (1.00) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL914324 | 0.78 | HRH3 (0.97) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL3156570 | 0.78 | HRH3 (0.97) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL3526680 | 0.77 | KCNJ1 (0.87) | MAOAKCNJ1KCNH2HRH3SIGMAR1 | |
| SCHEMBL4315787 | 0.76 | MAOA (0.71) | MAOAHRH3MAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | MAOA 1263/4885KCNJ1 3451/4885KCNH2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.